<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172924</url>
  </required_header>
  <id_info>
    <org_study_id>DSCGVHD001</org_study_id>
    <nct_id>NCT02172924</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease</brief_title>
  <official_title>A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy using decidual stromal cell
      therapy for graft versus host disease after allogeneic hematopoietic stem cell
      transplantation. The hypothesis to be tested is that the cells are safe to infuse and that
      they have a positive clinical effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1x10^6
      cells/kg at one or more occasions at weekly intervals dependent on clinical response.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actuarial survival at one year after onset of graft versus host disease</measure>
    <time_frame>12 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at 28 days after onset of graft versus host disease</measure>
    <time_frame>28 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Up to 6 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infections</measure>
    <time_frame>Up to 12 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>12 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Early Decidual Stromal Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Decidual Stromal Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Early Decidual stromal cell therapy</intervention_name>
    <description>Intervention given within 7 days after corticosteroids.</description>
    <arm_group_label>Early Decidual Stromal Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Late Decidual stromal cell therapy</intervention_name>
    <description>Intervention given after 7 days after corticosteroids.</description>
    <arm_group_label>Late Decidual Stromal Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute graft versus host disease grade 2-4 or therapy resistant chronic graft versus
             host disease.

          -  Are on calcineurin inhibitor and high dose corticosteroids.

        Exclusion Criteria:

          -  Terminally ill patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olle Ringdén, MD, PhD</last_name>
    <phone>+46858582672</phone>
    <email>olle.ringden@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen Kaipe, PhD</last_name>
    <phone>+46700901052</phone>
    <email>helen.kaipe@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <phone>+858582672</phone>
      <email>olle.ringden@ki.se</email>
    </contact>
    <investigator>
      <last_name>Olle Ringdén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>November 8, 2014</last_update_submitted>
  <last_update_submitted_qc>November 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Olle Ringdén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Decidual Stromal Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

